ライフサイエンスコーパス: intravaginal

1 Distinct differences were observed in intravaginal 50% infectious doses and in challenge infec

2 Intravaginal administration of CMP-Kdn or CMP-Leg5,7Ac2

3 Importantly, intravaginal administration of CMP-Leg5,7Ac(2) attenuate

4 Here, we show for the first time that intravaginal administration with nanoparticles of poly(l

5 ompartmentalized, being induced primarily by intravaginal administration.

6 explants from rhesus macaques, treated with intravaginal aerosolized mRNAs, show robust protection a

7 d waned, the 3 animals became infected after intravaginal and/or intravenous rechallenge.

8 Intravaginal antigenic challenge represents a novel appr

9 vaginal lavage (CVL) samples collected after intravaginal application of 0.5% PRO 2000 gel (Indevus).

10 Animals received a single intravaginal application of 15 microL of a 10% PRO 2000

11 Intravaginal application of siRNAs targeting the HSV-2 U

12 retains substantial antiviral activity after intravaginal application.

13 Single and repeated intravaginal applications of MB66 film were safe, well t

14 Only i.m. prime followed by intravaginal boost induced concomitant strong systemic a

15 Intravaginal boost with vectors expressing vaccine Ags w

16 erated in the cervicovaginal mucosa upon HPV intravaginal boost.

17 from symptomatic infection following a live intravaginal Candida challenge had increased VEC anti-Ca

18 d protection against disease and death after intravaginal challenge and markedly lowered the titers o

19 body were completely resistant to repetitive intravaginal challenge by a heterosexually transmitted f

20 ing Ad5gp vaccination were more resistant to intravaginal challenge by recombinant vaccinia virus exp

21 rred significantly higher protection against intravaginal challenge infection by the HSV-2 186 strain

22 Intravaginal challenge led to systemic infection in fema

23 Similar to previous findings, intravaginal challenge of C57BL/6 mice with hypha-defect

24 V, we developed an animal model based on the intravaginal challenge of female rhesus monkeys with SHI

25 Consistent with these findings, intravaginal challenge of macaques with SIV(mac251) prei

26 In contrast, fungal burden induced by intravaginal challenge of nearly all (97%) isolates was

27 Upon intravaginal challenge of these orally immunized mice wi

28 ct HIV-1 infection after HIV-Du151.2env-NLuc intravaginal challenge was increased ~4-fold in hCD4/R5/

29 O 2000 vaginal gel formulation 20 s prior to intravaginal challenge with 4.0 log10 pfu of herpes simp

30 ed in enhanced protection against a low-dose intravaginal challenge with a heterologous strain of SIV

31 eby vaginal immunity could be detected after intravaginal challenge with Candida antigen.

32 e to the SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239.

33 as sufficiently potent to protect against an intravaginal challenge with recombinant vaccinia virus e

34 -mediated control of viral replication after intravaginal challenge with SIVmac239.

35 Upon intravaginal challenge with SIVmac251, both persistently

36 Using a stringent repeated low-dose intravaginal challenge with the highly pathogenic SIVmac

37 cervicovaginal viral titers 1,000-fold after intravaginal challenge with vaccinia virus expressing th

38 wild-type, but not FcRn knockout, mice after intravaginal challenge with virulent HSV-2 186.

39 rus by delivery of 17beta-estradiol prior to intravaginal challenge with wild-type GBS 874391.

40 rom local or systemic herpetic disease after intravaginal challenge with wild-type HSV-1 or HSV-2.

41 CD4(+) and CD8(+) T cells prior to secondary intravaginal challenge, we identified lymphocyte populat

42 ing immunization and in vaginal washes after intravaginal challenge.

43 hanced protection against repeated low-dose, intravaginal challenges with heterologous SIVsmE660 in a

44 infection following 12 consecutive low-dose intravaginal challenges with simian-HIV strain SF162P3,

45 cine control animal, resisted two successive intravaginal challenges with SIV(mac251) and failed to s

46 rom transmission following repeated low-dose intravaginal challenges with SIVmac251.

47 In multivariable analysis, only intravaginal cleansing (practiced by 20.9%) was associat

48 ts and 100% of Ugandan participants reported intravaginal cleansing during the six week study period.

49 of sexual activity, and it is possible that intravaginal cleansing is a marker for unreported sexual

50 While intravaginal cleansing was commonly practiced in both co

51 d sexual debut, and this was associated with intravaginal cleansing.

52 in evidence of BV were randomized to receive intravaginal clindamycin or metronidazole.

53 his study was to evaluate the efficacy of an intravaginal cooling device (Vlisse) in women with VVC t

54 Intravaginal cooling provides clinical cure for VVC and

55 omplementary tool to systematically evaluate intravaginal DDS performance as a function of drug diffu

56 Mice received 14 daily intravaginal doses of nonoxynol-9, PRO 2000, or placebo

57 arized cultures and testing whether repeated intravaginal dosing potentiates the susceptibility of mi

58 Intravaginal drug and therapeutic delivery targeting dis

59 Intravaginal drug delivery can elicit a local effect, or

60 A variety of intravaginal drug delivery systems (DDS) including cream

61 There are a number of emerging areas in intravaginal drug delivery, but the vagina is a challeng

62 followed by an overview of polymeric gels in intravaginal drug delivery.

63 The primary endpoint was intravaginal ejaculatory latency time (IELT) measured by

64 The intravaginal ejaculatory latency time remains the primar

65 duce prolapse recurrence, but the effects of intravaginal estrogen on surgical prolapse management ar

66 I 0.58 to 0.87), as well as vaginal atrophy (intravaginal ET), sexual function, vertebral and nonvert

67 R in whole blood samples of females from any intravaginal experimental group and only detected in 20%

68 Postexposure prophylaxis (PEP) after intravaginal exposure to human immunodeficiency virus (H

69 n vitro could protect macaques from repeated intravaginal exposure to low doses of a simian immunodef

70 lymph nodes that rapidly expanded following intravaginal exposure to SIV(mac251.) HPV PsV-based vehi

71 V enters the vaginal mucosa within 60 min of intravaginal exposure, infecting primarily intraepitheli

72 Rechallenge with two sequential SIVmac251 intravaginal exposures again resulted in partial protect

73 Following 14 weekly intravaginal exposures to the highly pathogenic SIV(mac2

74 Although intravaginal formulations of topical azole antifungals a

75 unding by indication, pregnancies exposed to intravaginal formulations of topical azoles were used as

76 The sensorial properties of intravaginal gels, and how these relate to user complian

77 inhibition of virus lesion development in an intravaginal guinea pig herpes simplex virus-2 assay.

78 -1) infections are acquired by women through intravaginal HIV exposure.

79 ital tract renders these mice susceptible to intravaginal HIV infection.

80 A single low-dose intravaginal HIV-1 challenge of humanized DRAG mice resu

81 no HSPC injection, were also susceptible to intravaginal HIV.

82 Intravaginal HPV prime/boost reduced cervicovaginal vira

83 ization with ALVAC-SIV vaccines, followed by intravaginal HPV-PsV-SIV/gp120 boosting, expanded and/or

84 y and severity of herpetic lesions following intravaginal HSV challenge.

85 he burden of latent infection resulting from intravaginal HSV-2 challenge, and a nucleic acid vaccine

86 After intravaginal HSV-2 challenge, the mock and UL19/UL47 ade

87 uccumb to lethal infection (p < 0.005) after intravaginal HSV-2 challenge.

88 d vaginal washing virus titers were measured intravaginal HSV-2 challenge.

89 ated in the LT beta-deficient mice following intravaginal HSV-2 infection even in the absence of the

90 y was to develop a nonhuman primate model of intravaginal human immunodeficiency virus (HIV) transmis

91 following intranasal (IN), sublingual (SL), intravaginal (I.Vag) and intrarectal (IR) administration

92 uate mucosal vaccines for protection against intravaginal (i.vag.) transmission in macaque models of

93 st Candida vaginal infection, established by intravaginal (i.vg.) inoculation of yeast cells in mice

94 the female mouse cervicovaginal mucosa after intravaginal immunization with human papillomavirus vect

95 viducts at various times following a primary intravaginal infection and after a challenge infection.

96 ce appeared to be as resistant to chlamydial intravaginal infection as wild-type mice based on the nu

97 but which is now pathogenic and establishes intravaginal infection efficiently.

98 protected humanized mice against repetitive intravaginal infection in a dose-dependent manner.

99 l-length Env and Gag immunogens, can prevent intravaginal infection in a stringent macaque/SIV challe

100 sexual transmission of LASV in rodents, and intravaginal infection is potentially conducive to intra

101 Our previous studies revealed that intravaginal infection of mice with a plasmid-deficient

102 We also assess the effects of IFNs on intravaginal infection of the FRT using ovariectomized m

103 Intravaginal infection with Chlamydia muridarum in mice

104 ng wild-type mice (C5(+/+)) did so following intravaginal infection with Chlamydia muridarum.

105 After intravaginal infection with Chlamydia, CCR7-deficient mi

106 Following intravaginal infection with HSV type 2, activated dendri

107 in the genital tract as early as 12 h after intravaginal infection with MoPn.

108 Intravaginal infection with plasmid-competent but not pl

109 s were detected in vaginal tissues following intravaginal infection with T. vaginalis but were not se

110 type mice support ZIKV replication following intravaginal infection, consistent with prior studies, a

111 These intravaginal infections of the mouse do not ascend effic

112 wever, T/F Envs derived from intrarectal and intravaginal infections were not different.

113 cells, but not CD4 cells, were reduced after intravaginal injection of complement-fixing anti-Thy-1.2

114 C. muridarum infection in mice following an intravaginal inoculation and confirmed the rapid ascent

115 y of upper genital tract pathology following intravaginal inoculation into mice compared to the paren

116 by repeated negative cultures) occurs after intravaginal inoculation of a low dose of pathogenic SIV

117 However, intravaginal inoculation of animals with these two SHIVs

118 DPI and RNA can also be detected at 35 DPI, intravaginal inoculation of artificial insemination flui

119 UL24-betagluc was not virulent after intravaginal inoculation of BALB/c mice in that all inoc

120 Nevertheless, intravaginal inoculation of C. albicans into both specie

121 Intravaginal inoculation of cats with feline immunodefic

122 Intravaginal inoculation of guinea pigs with UL24-betagl

123 Intravaginal inoculation of HSV-2 led to a rapid recruit

124 Intravaginal inoculation of mice with an attenuated stra

125 Intravaginal inoculation of mice with C. albicans strain

126 Thus, transient viremia following intravaginal inoculation of pathogenic SIV is associated

127 r SHIV will produce systemic infection after intravaginal inoculation of rhesus macaques.

128 data from eight (donor) monkeys infected by intravaginal inoculation of SIVmac251, three monkeys inf

129 Intravaginal inoculation of the TC0668 null mutant into

130 of nectin-1 to mediate viral entry following intravaginal inoculation was examined in a mouse model o

131 mouse model of ascending infection following intravaginal inoculation with a strain of Chlamydia trac

132 A single atraumatic intravaginal inoculation with a T-cell-tropic molecular

133 n spinal cords of mice up to 10 months after intravaginal inoculation with a thymidine kinase-deficie

134 PMNs at the vaginal mucosal surface prior to intravaginal inoculation with an attenuated HSV-2 strain

135 the murine vaginal mucosa within 24 h after intravaginal inoculation with an attenuated strain of he

136 Intravaginal inoculation with C. muridarum readily induc

137 y intraperitoneal injection before and after intravaginal inoculation with C. trachomatis.

138 x development in wild-type mice following an intravaginal inoculation with Chlamydia Since T cells in

139 ravenous inoculation predicts the outcome of intravaginal inoculation with each virus.

140 l 5 strains developed hydrosalpinx following intravaginal inoculation with plasmid-competent, but not

141 Following intravaginal inoculation with primarily Opa- gonococci,

142 either progesterone or estrogen followed by intravaginal inoculation with SIVmac.

143 Intravaginal inoculation with T cell-tropic molecular cl

144 Following intravaginal inoculation, a C. muridarum strain deficien

145 Following an intravaginal inoculation, live chlamydial organisms were

146 cytokine production in the oviduct than the intravaginal inoculation, suggesting that the oviduct in

147 iruses will produce systemic infection after intravaginal inoculation, the level to which a virus rep

148 positive time point after low- and high-dose intravaginal inoculation.

149 nous inoculation does predict the outcome of intravaginal inoculation.

150 virus to initiate a systemic infection after intravaginal inoculation.

151 ability to infect rhesus macaques following intravaginal inoculation.

152 tion of the gastrointestinal tract following intravaginal inoculation.

153 d Asah1(-/-) mice die soon after systemic or intravaginal inoculation.

154 n the mouse lower genital tract following an intravaginal inoculation.

155 been infected by exposure to at least three intravaginal inoculations of SHIV 89.6.

156 It has previously been shown that 12 intravaginal inoculations with SIVmac1A11 resulted in in

157 In both countries, intravaginal insertion (e.g. with herbs) was less common

158 s expressing vaccine Ags was far superior to intravaginal instillation of CXCR3 chemokine receptor li

159 level of transport was evident at 4 hr after intravaginal instillation, and transport peaked at about

160 ) and histamine were increased 16-18 h after intravaginal introduction of Candida skin test antigen.

161 ted from infection or clinical disease after intravaginal (IVAG) challenge with pathogenic SIVmac239.

162 Here we evaluated intravaginal (ivag) genetic immunization of C57BL/6 mice

163 intramuscular (i.m.), intranasal (i.n.), or intravaginal (IVAG) immunization with VEE/SIN-Gag and an

164 Intravaginal (IVAG) inoculation of wild-type herpes simp

165 e (10(3) 50% tissue culture infective doses) intravaginal (IVAG) inoculations with simian immunodefic

166 ucosa would be more effectively increased by intravaginal (Ivag) therapeutic immunization compared to

167 In the present study, an intravaginal live Candida challenge in healthy adult wom

168 rasound-guided intrauterine LPS injection or intravaginal LPS administration could induce PTB by stim

169 Intravaginal LPS administration did not stimulate PTB.

170 Artificial intravaginal mechanical stimulation was sufficient to el

171 major neuromodulatory system and shows that intravaginal mechanosensory stimulation is necessary and

172 en from the United States and Kenya received intravaginal metronidazole (750 mg) plus miconazole (200

173 nya with a recent vaginal infection received intravaginal metronidazole 750 mg plus miconazole 200 mg

174 Bacterial vaginosis was treated with intravaginal metronidazole gel (0.75%), 37.5 mg nightly

175 Monthly treatment with intravaginal metronidazole plus miconazole reduced the p

176 by Amsel criteria were treated with oral or intravaginal metronidazole.

177 t evidence for the protective efficacy of an intravaginal microbicide/vaccine or microbivac platform

178 The effect on normal vaginal flora of three intravaginal microbicides potentially active against hum

179 C. sordellii infections were associated with intravaginal misoprostol administration, suggesting that

180 Our data present novel drug compositions for intravaginal mRNA delivery to prevent HIV acquisition an

181 levant placebo, or no treatment, followed by intravaginal N. gonorrhoeae challenge.

182 After intravaginal or intracranial inoculation of adult mice,

183 to systemic (oral or transdermal) and local (intravaginal or intrauterine).

184 gD1) provided 100% protection against lethal intravaginal or skin challenges and prevented latency.

185 n strategies, fluid management, medications, intravaginal pessaries, intravesical injection of botuli

186 were studied to determine whether the use of intravaginal practices (cleaning with the fingers, wipin

187 Intravaginal practices (IVP) are highly prevalent in sub

188 depot medroxyprogesterone acetate (DMPA) and intravaginal practices may be associated with human immu

189 This study evaluated the effect of DMPA and intravaginal practices on the genital proteome and micro

190 ace-to-face interview on sexual behavior and intravaginal practices, and a nurse-assisted self-admini

191 An HPV intravaginal prime/boost with different HPV serotypes in

192 une mice and could be detected by 24 h after intravaginal reinoculation.

193 ant reductions in the extent and duration of intravaginal replication of challenge HSV-1 and HSV-2 co

194 ted multipurpose prevention technology (MPT) intravaginal ring (IVR) for prevention of HIV, HSV-2, an

195 atrix, hydrophilic polyether urethane (HPEU) intravaginal ring (IVR) for sustained delivery of the an

196 hormonal contraceptive levels delivered via intravaginal ring (IVR) in a regimen-specific manner.

197 Here, we describe a novel core-matrix intravaginal ring (IVR), the MZCL IVR, which effectively

198 therapy (ART) and hormones released from an intravaginal ring are not known.

199 one exposure was significantly lower when an intravaginal ring contraceptive was combined with efavir

200 codynamic endpoints, such as ovulation, when intravaginal ring hormones are combined with efavirenz a

201 ive pharmacokinetic sampling at entry before intravaginal ring insertion and before intravaginal ring

202 (AUC(0-8 h)) were compared before and after intravaginal ring insertion by GMR (90% CI) and Wilcoxon

203 s were collected on days 7, 14, and 21 after intravaginal ring insertion.

204 sess the safety and pharmacokinetics of this intravaginal ring over 90 days in sexually active women.

205 conditions that were contraindicated in the intravaginal ring product labelling.

206 An intravaginal ring releasing etonogestrel and ethinylestr

207 efore intravaginal ring insertion and before intravaginal ring removal on day 21.

208 Intravaginal ring technology is generally limited to rel

209 An intravaginal ring that releases the tenofovir prodrug, t

210 On day 21 of intravaginal ring use, participants receiving efavirenz

211 ptability of a tenofovir disoproxil fumarate intravaginal ring used continuously with monthly ring ch

212 g an etonogestrel/ethinyl estradiol (ENG/EE) intravaginal ring while on no ART (n = 25), efavirenz-ba

213 ptive transdermal patch, a hormone-releasing intravaginal ring, new formulations of pills, and a new

214 trations would be unchanged during use of an intravaginal ring.

215 Intravaginal rings (IVRs) may improve efficacy by provid

216 We propose the use of 3D printed intravaginal rings (IVRs) to enable sustained delivery o

217 90 days continuous-delivery tenofovir (TFV) intravaginal rings (IVRs) with/without levonorgestrel (L

218 ve systems that include transdermal patches, intravaginal rings (IVRs), intrauterine devices (IUDs),

219 sumed to be low cost and highly efficacious; intravaginal rings targeted to sex workers; and vaccines

220 o the extent assumed, emphasis on oral PrEP, intravaginal rings, and long-acting antiretroviral drugs

221 w interventions in the medium term (offering intravaginal rings, long-acting injectable antiretrovira

222 ompass different delivery modalities such as intravaginal rings, subcutaneous implants, and intramusc

223 iversity of drugs that can be delivered from intravaginal rings, we designed an IVR that contains a d

224 al medication, the transdermal patch and the intravaginal route are starting to be used in clinical p

225 Immunization by the intravaginal route resulted in greater stimulation of va

226 inoculated by either the intravenous or the intravaginal route.

227 months later with pathogenic SHIVKU-1 by the intravaginal route.

228 on against virulent SHIV administered by the intravaginal route.

229 e animal infectious dose of the virus by the intravaginal route.

230 us (SHIV(KU-1)) to inoculate macaques by the intravaginal route.

231 h cell-free SHIV-E-CAR by the intravenous or intravaginal route; virus replicated in these animals bu

232 ne Ags, we assessed combinations of i.m. and intravaginal routes in heterologous prime-boost immuniza

233 c probiotic supplementation through oral and intravaginal routes in the prevention of recurrent UTIs.

234 infected with SIVagm by both intrarectal and intravaginal routes, (ii) susceptibility to infection is

235 monkeys efficiently by both intrarectal and intravaginal routes, replicated to high levels during ac

236 three rhesus macaques by the intravenous and intravaginal routes, respectively.

237 ious routes of infection, including oral and intravaginal routes, to mimic natural routes of transmis

238 that the MVA-ID vaccinations protect against intravaginal SHIV challenges by modulating the innate an

239 s type 2 (HSV-2) in mice can be inhibited by intravaginal siRNA application.

240 hat transpire from hours to a few days after intravaginal SIV exposure through week 4 to provide a fr

241 cated in draining lymph nodes within 18 h of intravaginal SIV exposure.

242 pe protein, and subsequent repeated low-dose intravaginal SIV exposures.

243 ng and infection following repeated low-dose intravaginal SIV exposures.

244 ne-treated animals became infected following intravaginal SIV inoculation.

245 d animals, except one, became infected after intravaginal SIV(mac251) low-dose challenge.

246 uximab (anti-CD20) 28 days and 7 days before intravaginal SIVmac239 inoculation and every 21 days the

247 uritian cynomolgus macaques against repeated intravaginal SIVmac251 challenges.

248 immunization strategies with intrarectal and intravaginal SIVsmE660 challenge of rhesus macaques.

249 on (SMD - 1.86, 95% CI - 2.77 to - 0.96) and intravaginal stimulation (SMD - 0.97, 95% CI - 1.55 to -

250 mulation was the most effective, followed by intravaginal stimulation.

251 PCR testing of wet and dry transported intravaginal swabs to detect chlamydia and gonorrhea inf

252 We assessed the accuracy of intravaginal swabs transported by mail in a wet versus a

253 To evaluate safety of intravaginal testosterone cream (IVT) or an estradiol-re

254 g could benefit the development of effective intravaginal therapies addressing female reproductive tr

255 To test the feasibility of localized intravaginal therapy directed to neighboring lymph nodes

256 tions provide protection from acquisition of intravaginal tier2 simian-human immunodeficiency virus (

257 pical dextran sulfate administration reduced intravaginal tissue damage and inflammation.

258 membrane-bound form, induced circulating and intravaginal-tissue-resident memory CD8(+) T cells that

259 It has different etiology than intravaginal torsion, which appears later in life.

260 Additionally, percutaneous tibial, intravaginal, transcutaneous tibial, and trans-sacral st

261 ficiency virus (SIV)-rhesus macaque model of intravaginal transmission of human immunodeficiency viru

262 ied topically prior to SIV(mac251) prevented intravaginal transmission of virus compared to controls

263 cyte loss in the SIV/rhesus macaque model of intravaginal transmission.

264 es associated with SIVsmE660 intrarectal and intravaginal transmissions in vaccinated and unvaccinate

265 eotide reductase 2 (RR2; prime), followed by intravaginal treatment with the neurotropic adeno-associ

266 ssing the toxicity of compounds intended for intravaginal use.

267 This study describes intravaginal vaccination with a nonreplicating HPV-based

268 Intravaginal vaccination with HPV-PsVs expressing SIV ge

269 Intravaginal vaccination with HPV16, HPV45, and HPV58 Ps

270 xposure to BCD and SIV(mac251) in subsequent intravaginal virus challenges (P = 0.63), despite the po

271 ce receiving estradiol are protected against intravaginal ZIKV infection, independently of IFN-alpha/